Gotenba, Japan

Shinsuke Uno


Average Co-Inventor Count = 3.9

ph-index = 3

Forward Citations = 61(Granted Patents)


Location History:

  • Gotemba, JP (2009 - 2010)
  • Gotenba, JP (2012 - 2014)

Company Filing History:


Years Active: 2009-2014

Loading Chart...
4 patents (USPTO):

Title: Shinsuke Uno: Innovator in Antibody Development

Introduction

Shinsuke Uno is a prominent inventor based in Gotenba, Japan. He has made significant contributions to the field of biotechnology, particularly in the development of humanized antibodies. With a total of 4 patents to his name, Uno's work is paving the way for advancements in therapeutic agents for hematological disorders.

Latest Patents

Uno's latest patents focus on humanized anti-CD47 antibodies. These inventions relate to humanized antibodies that bind to CD47, including diabodies characterized by a disulfide bond between diabody-forming fragments. His patents also encompass genes encoding these antibodies, vectors containing said genes, and host cells that harbor these vectors. Furthermore, the processes for preparing these antibodies involve culturing the host cells, leading to the development of therapeutic agents for hematological disorders.

Career Highlights

Shinsuke Uno is currently associated with Chugai Seiyaku Kabushiki Kaisha, a leading pharmaceutical company in Japan. His work at Chugai has been instrumental in advancing the company's research and development efforts in antibody therapies.

Collaborations

Uno collaborates with notable colleagues, including Naoshi Fukushima and Yasufumi Kikuchi. Their combined expertise contributes to the innovative research being conducted in the field of antibody development.

Conclusion

Shinsuke Uno's contributions to the field of biotechnology, particularly in the development of humanized antibodies, highlight his role as a key innovator. His work continues to influence advancements in therapeutic solutions for hematological disorders.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…